Agilent Technologies (A)
Forward P/E is 27.82x against a peer median of 30.89x, a ratio of 0.90x — at the cheap edge of the fair range — with trailing P/E 36.03x and PEG 2.63. Latest-quarter revenue grew 8.1% year over year (PRIMARY, EDGAR), exactly in line with the cluster pace; the move to undervalued is not met because the PEG of 2.63 is well above about 1.2, even though the ratio and growth tests are met. Delivered demand check: the Life sciences tools & services group's median growth was 8.1% year over year — demand rising, and Agilent grew exactly in line with that median.
What would change this label: Move to UNDERVALUED if the forward P/E compresses to about 27.80x or below (0.90x the peer median) at unchanged estimates while the PEG falls to about 1.2 or below, or if revenue growth rises above 12% year over year for two quarters with the PEG below about 1.2. Move to OVERVALUED if the forward P/E rises above about 35.52x (1.15x the peer median) without a matching rise in growth.
Agilent makes laboratory instruments used to test samples in science, food and industry. Its shares cost about 28 times next year's expected earnings, slightly below similar companies at about 31 times, while its sales grew about 8%, exactly in line with its group. On those numbers the shares look fairly priced.
Both lines start at 100 on 2020-09-01. Over the full window Agilent Technologies returned +75.52% and the S&P 500 +118.28% (price returns; dividends not reinvested). Worst peak-to-trough fall for Agilent Technologies: -44.6% (2021-09-03 to 2025-04-08). Source: Nasdaq official daily history.
What the label rests on
Forward P/E is 27.82x against a peer median of 30.89x, a ratio of 0.90x — at the cheap edge of the fair range — with trailing P/E 36.03x and PEG 2.63. Latest-quarter revenue grew 8.1% year over year (PRIMARY, EDGAR), exactly in line with the cluster pace; the move to undervalued is not met because the PEG of 2.63 is well above about 1.2, even though the ratio and growth tests are met. Delivered demand check: the Life sciences tools & services group's median growth was 8.1% year over year — demand rising, and Agilent grew exactly in line with that median. The company’s forward P/E is 27.8× against a peer median of 30.9×. Its own history: UNVERIFIED — no sourced range available. Sector demand read: Delivered demand check: the Life sciences tools & services group's median latest-quarter revenue growth was 8.1% year over year (SEC filings) — demand rising. Agilent grew exactly in line with that median, at 8.1%. Latest-quarter sales growth was +8.1% versus a year earlier (SEC filings).
| Company | Price (Oct 28, 2026) | Forward P/E | Trailing P/E |
|---|---|---|---|
| Agilent Technologies (A) | $182.73 | 27.8× | 36.0× |
| WAT | — | 30.9× | 216.8× |
| IQV | — | 20.2× | 34.0× |
| ILMN | — | 51.0× | 54.1× |
| MTD | — | 34.9× | 38.6× |
| CRL | — | 30.6× | — |
| Peer median | 30.9× |
Multiples: stockanalysis.com (SECONDARY, S&P Global data), fetched Oct 28, 2026. Peer set chosen by sector; the median is the middle value of the set. The label and its numbers were recorded in the programme’s label registry on Oct 28, 2026 and will be scored at 6 and 12 months.
Sales, profit and cash
This company does not report a gross-profit line in its SEC facts (normal for banks, payment networks and some health insurers), so profit is shown as net income instead — gross margin is marked UNVERIFIED-absent rather than estimated.
Free cash flow = cash from operations minus spending on plant and equipment, both from the company’s SEC cash-flow statement. Gaps are quarters where that spending line is not separately tagged in the filings — shown as gaps, never estimated.
| Quarter | Sales | Gross margin | Net income | EPS (GAAP, diluted) | Free cash flow |
|---|---|---|---|---|---|
| Q/E Jul 2026 2026-07-31 | $1.9B | — | $362M | 1.28 | $439M |
| Q/E Apr 2026 2026-04-30 | $1.8B | — | $339M | 1.20 | $201M |
| Q/E Jan 2026 2026-01-31 | $1.8B | — | $305M | 1.07 | $175M |
| Q/E Oct 2025 2025-10-31 | $1.9B | — | $434M | — | $452M |
| Q/E Jul 2025 2025-07-31 | $1.7B | — | $336M | 1.18 | $259M |
| Q/E Apr 2025 2025-04-30 | $1.7B | — | $215M | 0.75 | $107M |
| Q/E Jan 2025 2025-01-31 | $1.7B | — | $318M | 1.11 | $334M |
| Q/E Oct 2024 2024-10-31 | $1.7B | — | $351M | — | $388M |
| Q/E Jul 2024 2024-07-31 | $1.6B | — | $282M | 0.97 | $360M |
| Q/E Apr 2024 2024-04-30 | $1.6B | — | $308M | 1.05 | $230M |
| Q/E Jan 2024 2024-01-31 | $1.7B | — | $348M | 1.18 | $395M |
| Q/E Oct 2023 2023-10-31 | $1.7B | — | $475M | — | $432M |
The last twelve reported quarters. Full 24-quarter history sits in the data pack behind this page. A dash means the figure is not tagged as a standalone quarter in the company’s SEC facts (the usual case is the fourth quarter, which many companies only report inside the full-year filing) — it is missing, not zero.
Earnings: getting better or worse?
Each box is one quarter’s earnings per share (EPS). Green means EPS was higher than the same quarter a year earlier; red means lower; a dash means the figure is not tagged in the filings.
Basis: GAAP diluted EPS from SEC company facts, compared with the same quarter a year earlier.
Key facts
| Item | Value |
|---|---|
| Company (legal name in filings) | AGILENT TECHNOLOGIES, INC. |
| Chief executive | Padraig McDonnell (source: https://en.wikipedia.org/wiki/Agilent_Technologies) |
| Sector | Health Care — Life Sciences Tools & Services — makes laboratory instruments and testing tools used in life-science, food and chemical analysis |
| Share price (Oct 28, 2026) | $182.73 |
| Market value (market cap) | $50.0B — share price times shares outstanding of 281,928,854 (SEC filings; SEC EDGAR dei EntityCommonStockSharesOutstanding (latest)) |
| Sales, last twelve months | $7.4B |
| Net income, last twelve months | $1.4B |
| Free cash flow, last twelve months | $1.3B |
| Latest reported quarter | Q/E Jul 2026 (of 24 quarters in the data pack) |
| Six-year price return vs S&P 500 | +75.52% vs +118.28% |
| Worst peak-to-trough fall | -44.6% (2021-09-03 to 2025-04-08) |
What we could not verify
- Gross profit / gross margin: not tagged as a standalone line in this company's EDGAR company facts (common for banks, payment networks and some healthcare payers) — shown as UNVERIFIED-absent; the page charts revenue and net income instead.
- TTM GAAP diluted EPS could not be summed from company facts because at least one of the last four quarters (typically Q4) has no standalone tagged EPS; trailing P/E is therefore taken from the labelled secondary source in valuation_label.md.
- Own-history P/E range not yet compiled for this company in the Phase 1 batch run; the label rests on peer-median, growth and PEG evidence.
- Guidance record (each quarter scored against the guidance the company gave the quarter before) is not yet compiled for this company — it is a Phase 2 layer. The earnings strip below therefore uses reported EPS versus a year earlier, which is fully sourced from filings.
The IT factor — the most exciting thing the market is overlooking — is not assessed on an X-Ray page. It belongs to the Deep Dive (Phase 2), where it gets the evidence standard it needs. Leadership-era scoring (the six years split by chief executive) is likewise a Phase 2 layer; this page names the current chief executive only, from a sourced profile.
Sources
- SEC EDGAR submissions — Filing index; company legal name.
https://data.sec.gov/submissions/CIK0001090872.json - SEC EDGAR company facts — Quarterly financial spine: revenue, gross profit, net income, GAAP diluted EPS, operating cash flow, PP&E capex, buybacks, dividends, diluted shares.
https://data.sec.gov/api/xbrl/companyfacts/CIK0001090872.json - Nasdaq official daily history — Daily closes for the company; SPY (assetclass=etf) saved as raw/nasdaq_spy_raw.json over identical dates.
https://api.nasdaq.com/api/quote/A/historical?assetclass=stocks - Valuation multiples and peer figures — stockanalysis.com (SECONDARY, S&P Global data), fetched Oct 28, 2026; see valuation_label.md in the data pack.
Conventions: earliest-filed value per period, as first reported; cash-flow years-to-date differenced quarter by quarter; EPS never differenced; free cash flow = operating cash flow minus plant-and-equipment spending. This page is a dated snapshot — updates are new versions, never silent edits.